Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytosorbents Cor
(NQ:
CTSO
)
1.420
+0.100 (+7.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytosorbents Cor
< Previous
1
2
Next >
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
August 27, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
August 13, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
August 13, 2024
CytoSorbents CFO Kathleen P. Bloch Retires
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
August 01, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
July 17, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Secures $20 Million Credit Facility
July 02, 2024
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
June 13, 2024
By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
June 24, 2024
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
June 05, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
June 04, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Reports First Quarter 2024 Results
May 09, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
May 02, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
April 26, 2024
From
CytoSorbents
Via
GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
April 17, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
March 06, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
February 08, 2024
From
CytoSorbents
Via
GlobeNewswire
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
January 17, 2024
CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction
From
CytoSorbents
Via
GlobeNewswire
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
January 08, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
December 13, 2023
Company insiders participated in the transaction with $435,000 of investment
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
November 09, 2023
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
October 27, 2023
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the 8th Annual Dawson James Conference
October 05, 2023
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
September 19, 2023
From
CytoSorbents
Via
GlobeNewswire
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
September 11, 2023
In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival
From
CytoSorbents
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.